170 related articles for article (PubMed ID: 10626810)
1. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.
Soriano AF; Helfrich B; Chan DC; Heasley LE; Bunn PA; Chou TC
Cancer Res; 1999 Dec; 59(24):6178-84. PubMed ID: 10626810
[TBL] [Abstract][Full Text] [Related]
2. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Chan DC; Earle KA; Zhao TL; Helfrich B; Zeng C; Baron A; Whitehead CM; Piazza G; Pamukcu R; Thompson WJ; Alila H; Nelson P; Bunn PA
Clin Cancer Res; 2002 Mar; 8(3):904-12. PubMed ID: 11895925
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
Bunn PA; Chan DC; Earle K; Zhao TL; Helfrich B; Kelly K; Piazza G; Whitehead CM; Pamukcu R; Thompson W; Alila H
Semin Oncol; 2002 Feb; 29(1 Suppl 4):87-94. PubMed ID: 11894018
[TBL] [Abstract][Full Text] [Related]
4. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.
Lim JT; Piazza GA; Han EK; Delohery TM; Li H; Finn TS; Buttyan R; Yamamoto H; Sperl GJ; Brendel K; Gross PH; Pamukcu R; Weinstein IB
Biochem Pharmacol; 1999 Oct; 58(7):1097-107. PubMed ID: 10484067
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
6. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.
Whitehead CM; Earle KA; Fetter J; Xu S; Hartman T; Chan DC; Zhao TL; Piazza G; Klein-Szanto AJ; Pamukcu R; Alila H; Bunn PA; Thompson WJ
Mol Cancer Ther; 2003 May; 2(5):479-88. PubMed ID: 12748310
[TBL] [Abstract][Full Text] [Related]
7. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.
Drugs R D; 2004; 5(4):220-6. PubMed ID: 15230629
[TBL] [Abstract][Full Text] [Related]
8. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth.
Moody TW; Leyton J; Martinez A; Hong S; Malkinson A; Mulshine JL
Exp Lung Res; 1998; 24(4):617-28. PubMed ID: 9659587
[TBL] [Abstract][Full Text] [Related]
9. Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations.
Sun SY; Schroeder CP; Yue P; Lotan D; Hong WK; Lotan R
Cancer Biol Ther; 2005 Apr; 4(4):407-13. PubMed ID: 15846100
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines.
Hida T; Kozaki K; Muramatsu H; Masuda A; Shimizu S; Mitsudomi T; Sugiura T; Ogawa M; Takahashi T
Clin Cancer Res; 2000 May; 6(5):2006-11. PubMed ID: 10815926
[TBL] [Abstract][Full Text] [Related]
11. Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells.
Joe AK; Liu H; Xiao D; Soh JW; Pinto JT; Beer DG; Piazza GA; Thompson WJ; Weinstein IB
J Exp Ther Oncol; 2003; 3(2):83-94. PubMed ID: 12822514
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
Jones SF; Kuhn JG; Greco FA; Raefsky EL; Hainsworth JD; Dickson NR; Thompson DS; Willcutt NT; White MB; Burris HA
Clin Lung Cancer; 2005 May; 6(6):361-6. PubMed ID: 15943897
[TBL] [Abstract][Full Text] [Related]
13. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Xie CY; Xu YP; Jin W; Lou LG
Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
Teicher BA; Korbut TT; Menon K; Holden SA; Ara G
Cancer Chemother Pharmacol; 1994; 33(6):515-22. PubMed ID: 8137463
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
Richter M; Weiss M; Weinberger I; Fürstenberger G; Marian B
Carcinogenesis; 2001 Jan; 22(1):17-25. PubMed ID: 11159736
[TBL] [Abstract][Full Text] [Related]
17. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.
Li J; Viallet J; Haura EB
Cancer Chemother Pharmacol; 2008 Mar; 61(3):525-34. PubMed ID: 17505826
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.
Sei S; Mussio JK; Yang QE; Nagashima K; Parchment RE; Coffey MC; Shoemaker RH; Tomaszewski JE
Mol Cancer; 2009 Jul; 8():47. PubMed ID: 19594950
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells.
Sun SY; Yue P; Dawson MI; Shroot B; Michel S; Lamph WW; Heyman RA; Teng M; Chandraratna RA; Shudo K; Hong WK; Lotan R
Cancer Res; 1997 Nov; 57(21):4931-9. PubMed ID: 9354460
[TBL] [Abstract][Full Text] [Related]
20. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
